Zenarestat
Zenarestat
Zenarestat (pronounced: zeh-nah-RE-stat) is an Aldose reductase inhibitor used in the treatment of diabetic neuropathy. It is an experimental drug and is not currently approved for use in any country.
Etymology
The name "Zenarestat" is derived from the pharmaceutical company that developed it, Zeneca, and the class of drugs it belongs to, Aldose reductase inhibitors.
Usage
Zenarestat is used in the treatment of diabetic neuropathy, a condition that affects the nerves in people with diabetes. It works by inhibiting the enzyme aldose reductase, which is involved in the conversion of glucose to sorbitol. This process is believed to contribute to the nerve damage seen in diabetic neuropathy.
Related Terms
- Aldose reductase inhibitor: A class of drugs that inhibit the enzyme aldose reductase. Zenarestat is a member of this class.
- Diabetic neuropathy: A type of nerve damage that can occur in people with diabetes. Zenarestat is used in the treatment of this condition.
- Zeneca: The pharmaceutical company that developed Zenarestat.
- Sorbitol: A sugar alcohol that the body uses slowly. It is believed to contribute to the nerve damage seen in diabetic neuropathy when its levels are high in the body.
See Also
External links
- Medical encyclopedia article on Zenarestat
- Wikipedia's article - Zenarestat
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski